Related Experiment Video
Updated: Mar 14, 2026
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Functional autoantibodies and coronary microvascular obstruction in STEMI: a translational link between immune
Laura Iop1, Giovanni Civieri2, Giacomo Bernava1
1Cardiovascular Disease Modeling and Regenerative Medicine, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Insights
Agonistic autoantibodies targeting angiotensin II type 1 (AT1R) and endothelin-1 type A (ETAR) receptors directly cause coronary microvascular obstruction (CMVO) in ST-elevation myocardial infarction (STEMI) patients. Receptor blockade may offer a protective strategy for high-risk STEMI individuals.
Area of Science:
- Cardiology
- Immunology
- Vascular Biology
Background:
- Coronary microvascular obstruction (CMVO) complicates ST-elevation myocardial infarction (STEMI) despite timely intervention, impairing outcomes.
- Agonistic autoantibodies to angiotensin II type 1 (AT1R) and endothelin-1 type A (ETAR) receptors are implicated in CMVO, but their direct role is unclear.
Purpose of the Study:
- To investigate the direct contribution of autoantibodies against AT1R and ETAR to CMVO in STEMI patients.
- To explore the potential of receptor antagonism as a therapeutic strategy.
Main Methods:
- Prospective enrollment of 287 STEMI patients to assess CMVO, remodeling, and clinical events.
- Isolation of immunoglobulins from high-titer autoantibody patients and controls for in vitro endothelial cell studies.
- Assessment of endothelial cell function, viability, and oxidative stress following immunoglobulin exposure, with and without receptor blockade.
Main Results:
- Higher autoantibody titers correlated with increased CMVO prevalence and poorer clinical outcomes.
- Patient-derived immunoglobulins induced endothelial dysfunction, cytoskeletal disruption, and oxidative stress in vitro.
- Receptor blockade of AT1R and ETAR significantly reduced endothelial injury and oxidative stress.
Conclusions:
- Agonistic autoantibodies against AT1R and ETAR directly damage coronary microvascular endothelium, replicating STEMI-related CMVO features.
- These findings highlight an immune-mediated mechanism contributing to microvascular injury.
- Receptor antagonism presents a promising, receptor-dependent strategy for microvascular protection in high-risk STEMI patients.
Background:
Despite timely primary percutaneous coronary intervention, coronary microvascular obstruction (CMVO) continues to limit myocardial reperfusion and worsen prognosis in patients with ST-elevation myocardial infarction (STEMI). Agonistic autoantibodies targeting the angiotensin II type 1 (AT1R) and endothelin-1 type A (ETAR) receptors have been associated with CMVO, but whether they directly contribute to microvascular injury remains unclear.
Methods:
We prospectively enrolled 287 STEMI patients and evaluated CMVO, left ventricular remodeling, and major adverse cardiovascular events during a median follow-up of 460 days. Immunoglobulins were isolated from a subset of patients with the highest AT1R-AA and ETAR-AA titers and from seronegative controls. Human cardiac microvascular endothelial cells were exposed to patient-derived or control immunoglobulins, with or without pharmacological receptor blockade.
Results:
Patients with higher autoantibody titers showed a greater prevalence of CMVO and worse clinical outcomes. In vitro, immunoglobulins from seropositive patients rapidly induced endothelial dysfunction, characterized by cytoskeletal disorganization, junctional disruption, endothelial activation, and increased mitochondrial oxidative stress. These alterations were most pronounced at 24 hours and progressed to reduced cell viability and increased cytotoxicity at 48 hours. Immunoglobulins from seronegative controls had no relevant effects. Blockade of AT1R and ETAR significantly mitigated endothelial injury and oxidative stress.
Conclusions:
Agonistic autoantibodies against AT1R and ETAR directly damage coronary microvascular endothelium and reproduce key features of CMVO observed in STEMI patients. These findings support a clinically relevant, immune-mediated mechanism of microvascular injury and suggest that receptor antagonism represents a biologically plausible, receptor-dependent mechanism warranting further investigation as a potential microvascular protective strategy in high-risk STEMI patients.
Related Concept Videos
01:30Acute Coronary Syndrome I: Introduction
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:30Coronary Artery Disease I: Introduction
01:21Myocarditis I: Introduction
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:26Coronary Artery Disease II: Pathophysiology